Key result
Heparinoid Org 10172 shows potential efficacy over standard heparin in acute ischemic stroke.
Why the study?
The heterogeneity of low-molecular-weight heparins has hampered their proper investigation in clinical trials and it is unproven that they have less hemorrhagic and thrombocytopenic risk than conventional heparin in acute ischemic stroke.
Does Org 10172 improve outcomes and lessen mortality compared to standard heparin in patients with acute or progressing ischemic stroke?
Does Org 10172 improve outcomes and lessen mortality compared to standard heparin in patients with acute or progressing ischemic stroke?
The LMW heparinoid Org 10172 shows potential for improving outcomes in acute ischemic stroke with less risk of thrombocytopenia than standard heparin, highlighting the need for randomized controlled trials.
Answers are grounded in this paper and cite their sources.
Org 10172 should not yet alter acute ischemic stroke management; leaves open comparative efficacy versus heparin pending RCTs.
Thrombotic or thromboembolic occlusion of a cerebral artery is the most common pathophysiologic mechanism of acute ischemic stroke. An antithrombotic agent would therefore appear to be an ideal medication for treatment of this condition. Heparin is an effective anticoagulant, but it has poor bioavailability and effects on thrombin and platelets that predispose it to life-threatening complications such as hemorrhage and thrombocytopenia. Low-molecular-weight (LMW) heparins have better bioavailability, a higher anti-Xa:anti-IIa ratio, and less effect on platelets than heparin; yet their heterogeneity has hampered their proper investigation in clinical trials and it has not yet been proven that they exhibit less tendency toward hemorrhage and thrombocytopenia than conventional heparin. The LMW heparinoid, Org 10172, is superior to standard heparin in terms of its bioavailability, anti-Xa:anti-IIa ratio, and lack of effect on platelets. It is less likely than heparin and many LMW heparins to induce thrombocytopenia. Like the various heparins, Org 10172 exhibits dose-dependent hemorrhagic tendencies, yet preliminary studies have found doses that are safe for use in patients with acute ischemic stroke. These studies also suggest that Org 10172 may improve outcome and lessen mortality in this population. A prospective, randomized, double-blind, controlled trial is needed to establish the potential efficacy of Org 10172 in patients who suffer acute or progressing ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Gordon et al. (1990) conducted a review in Acute or progressing ischemic stroke. Low-molecular-weight heparins and heparinoids (Org 10172) vs. Standard heparin was evaluated. The low-molecular-weight heparinoid Org 10172 shows potential efficacy and safety for acute ischemic stroke compared to standard heparin, but requires validation in a randomized controlled trial.
Synapse has enriched 10 related papers. Consider them for comparative context: